Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use
Allergan is introducing Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use.
Restasis is approved for patients with chronic dry eye disease...also called keratoconjunctivitis sicca.
Chronic dry eye disease is caused by chronic inflammation, aging, or autoimmune disorders such as Sjögren's syndrome.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote